Cryo-Cell Announces Strategic Partnership With S-Evans Bioscie...(ells and genomics that may contribute a ...)

The strategic partnership between Cryo-Cell International and S-Evans Biosciences comes at an excellent time for healthcare in China. The Chinese government has announced a new healthcare reform plan that is expected to allocate considerable resources towards stem cell research and development. The government also considers women's health an area of priority and has continued to support expansion and improvement of women's healthcare services and institutes throughout the country.

"We are both honored and excited to partner with distinguished professor and CEO Dr. Xiang and his colleagues at S-Evans Biosciences to operationalize their license of Cryo-Cell's proprietary C'elle menstrual stem cell technology. We anticipate that C'elle will provide the opportunity for women across mainland China to harvest and cryopreserve their own stem cells for potential therapeutic utilization in the future," said Mercedes A. Walton, Cryo-Cell's Chairman and CEO. "We are clearly encouraged by the overall pace of clinical advances in stem cell therapeutic development underway in China. We share SEB's belief that there may possibly be a vast pipeline of potential opportunity to collaborate on the possible development of future therapies using menstrual stem cell technology."

The C'elle service is based on Cryo-Cell's expansive patent pending IP technology portfolio and was introduced in November, 2007 as the first and only service that empowers women to collect and cryopreserve menstrual flow containing undifferentiated adult stem cells for future potential utilization by the donor or possibly first-degree relatives in a manner similar to umbilical cord blood stem cells. Based on the continued success of MenSCs in the research setting, Cryo-
'/>"/>